

LTR Pharma to List on the ASX

8 December 2023

Highlights:

- LTR Pharma shares to commence trading on the Australian Securities Exchange (ASX) on 11 December 2023 at 11:00 AM (AEDT) under the ticker code ASX:LTP.
- The heavily oversubscribed IPO raised A\$7m at \$0.20 per share.
- Capital raised will be used to advance SPONTAN® on its expedited commercial pathway.

LTR Pharma Limited (ASX:LTP) ("LTR Pharma", "the Company"), a Company focused on holistically improving men's health through the clinical development and commercialisation of an innovative intranasal spray treatment for Erectile Dysfunction ("ED"), SPONTAN®, is pleased to announce that the Company's shares will commence trading on the Australian Securities Exchange (ASX) on 11 December 2023 at 11:00 AM (AEDT) under the ticker code ASX:LTP.

Last week the Company successfully raised A\$7m from new and existing shareholders through an oversubscribed IPO at an issue price of \$0.20 per share, with Alpine Capital acting as lead manager.

The proceeds from the raise will be used to advance SPONTAN on its accelerated commercial pathway to market, including a bioequivalence study and anticipated expedited regulatory filings in Australia and the United States within 1-2 years, with capital also being used for sales, marketing, and general working capital.

ED is a condition in which a person is unable to get or keep an erection firm enough for satisfactory sexual intercourse, and is a serious health issue for millions of men that can harm their self-esteem and relationships, at any age.

The Company's lead product SPONTAN differs from existing ED therapies by its mechanism of action – intranasal delivery of an already proven, effective and regulatory-cleared PDE5 inhibitor. Its unique composition and delivery mechanism is designed to bypass first-pass metabolism associated with many oral PDE5 medications.

LTR Pharma is planning to pursue the expedited FDA 505(b)(2) regulatory process, which governs a change of route in administration of an already approved drug. The Company received approval from the Bellberry Human Research Ethics Committee ("HREC") for a bioequivalence clinical trial comparing its proprietary multi-use Nasal Spray SPONTAN with the FDA approved ED drug Levitra®.

The proposed trial will compare the pharmacokinetics, safety and tolerability of Vardenafil following administration of LTR's Nasal Spray (SPONTAN) and Levitra® tablets in healthy male adults. Patient recruitment is expected early next year, with trial sites to open in Sydney, Australia in Q1 CY24.

Commenting on the ASX listing, LTR Pharma Chairman, Lee Rodne, said:

"We are deeply encouraged by the support we have received from our new and existing shareholders as part of the IPO journey for LTR Pharma. This is an exciting chapter, with funds raised to be directly applied to fast tracking SPONTAN to commercialisation."

“By 2025, over 322 million men globally are expected to be affected by ED¹ and the global market for ED treatments is forecasted to grow from US\$3.6 billion in 2021 to US\$5.9 billion by the end of 2028. This presents a significant commercial opportunity for SPONTAN.

“With a unique competitive advantage, and consumer demand clearly warranting new and innovative treatments in this market category, LTR Pharma is strongly positioned to capitalise on the rapidly growing demand for effective and rapid ED treatments.

“We look forward to an exciting 2024 and beyond as an ASX-listed company, and I would like to thank shareholders for their support to date.”

This announcement has been approved by the Board of Directors.

For further information please contact:

Haley Charters
Media Relations
haley@hck.digital

Jane Morgan
Investor Relations
jm@janemorganmanagement.com.au

About LTR Pharma

LTR Pharma is a public company, with operations based in Brisbane, Australia. Our focus is on holistically improving men’s health, physically and mentally, through the commercialisation of an innovative intranasal spray treatment for Erectile Dysfunction (ED).

ED is a pressing health issue for millions of men that can negatively impact self-esteem and relationships, across multiple age brackets.

LTR Pharma’s lead product SPONTAN® is set apart from existing ED therapies by its mechanism of action – intranasal delivery technology of a PDE5 inhibitor. The nasal cavity is a highly vascular part of the body supporting even and rapid absorption of the drug, empowering it to work within 10 minutes or less.

LTR Pharma is proudly aiming to restore greater control over the timing, spontaneity, and enjoyment of sexual experiences.

¹ Frost and Sullivan Report, The Erectile Dysfunction Medicines Market, September 2023